News and Press Releases
Clinical Trial Media Has Increased Patient Randomisations Up to 50% Among Participants Enrolled Through Its Human-Tech Recruiting Approach
With 50 new on-staff nurses and its machine learning-powered pre-screening technology driving a 15% increase in qualified clinical trial candidates, the trial recruitment company is complementing tech efficiencies with personalised...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 11, 2024
Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies
July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...
Category: Drug Delivery
Posted: July 11, 2024
Concr launches trial using digital twins for outcome prediction in breast cancer
10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...
Category: Biotechnology
Posted: July 10, 2024
Pascal Piedbois MD PhD joins One2Treat as chief medical officer to advance patient-centric innovation in clinical trial design and market access
One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments. 9 July 2024 -- Brussels, Belgium -- In this...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: July 10, 2024
Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer
Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024
Spur provides update on FLT201 and planned phase III clinical trial
8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company...
Category: Clinical Trials, Other, Pharmaceutical
Posted: July 8, 2024
Stockholm 3 commercially available in the US
A3P Biomedical AB, a leading Swedish diagnostics company specializing in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, are excited to announce that Stockholm3 for early detection...
Category: Biotechnology
Posted: July 3, 2024
Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
Phase 2b Influenza Field Study Contract
hVIVO to enrol up to 1,000 healthy volunteers as part of a multicentre field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site Largest...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024
1nhaler hires pharma industry leaders for key roles ahead of clinical trials
Edinburgh-based 1nhaler has appointed two experts in inhalation and respiratory medicines to the board as it looks to accelerate the development and market-readiness of its novel single use inhaler device....
Category: Clinical Trials, Other
Posted: July 1, 2024
RYBREVANT (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Approval is supported by the phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60% compared to chemotherapy alone 28...
Category: Clinical Trials, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
CHMP adopts positive opinion for BALVERSA (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers The CHMP’s recommendation is based on results...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 28, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
New study investigates link between toxic element exposure and Alzheimer’s disease risk
25 June 2024 -- Malvern, UK -- A comprehensive study is currently underway to clarify the relationship between Alzheimer's disease and related dementias (AD/ADRD) and four toxic elements: lead, mercury, arsenic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 27, 2024
Prevention and early detection of gastrointestinal cancers take on new importance amidst a younger population
Emerging research on early-onset gastrointestinal cancers highlights need for better prevention, diagnosis and treatment Less invasive, smart technologies could improve participation in and efficacy of GI cancer screening Studies presented...
Category: Other
Posted: June 27, 2024
Thermo Fisher Scientific Expands Clinical Research Laboratory in Kentucky
The PPD clinical research business will nearly double its laboratory footprint in northern Kentucky, add more than 250 jobs 27 June 2024 -- North Carolina, US -- The PPD clinical...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 27, 2024
